Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy
Moustafa, A., Nabil, N., Soliman, Z., Mohamed, Y., Elgarem, H., Eletreby, R. (2024). Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy. EKB Journal Management System, 5(3), 1007-1019. doi: 10.21608/mid.2024.286104.1922
Ahmed Moustafa; Nouran Nabil; Zeinab Abdellatif Soliman; Yomna Mohamed; Hasan Elgarem; Rasha Eletreby. "Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy". EKB Journal Management System, 5, 3, 2024, 1007-1019. doi: 10.21608/mid.2024.286104.1922
Moustafa, A., Nabil, N., Soliman, Z., Mohamed, Y., Elgarem, H., Eletreby, R. (2024). 'Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy', EKB Journal Management System, 5(3), pp. 1007-1019. doi: 10.21608/mid.2024.286104.1922
Moustafa, A., Nabil, N., Soliman, Z., Mohamed, Y., Elgarem, H., Eletreby, R. Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy. EKB Journal Management System, 2024; 5(3): 1007-1019. doi: 10.21608/mid.2024.286104.1922

Value of autotaxin as a serum marker for liver fibrosis in chronic HCV infected patients receiving direct-acting antiviral therapy

Microbes and Infectious Diseases
Article 13, Volume 5, Issue 3, August 2024, Page 1007-1019  XML PDF (717.87 K)
Document Type: Original Article
DOI: 10.21608/mid.2024.286104.1922
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Moustafa email 1; Nouran Nabil2; Zeinab Abdellatif Solimanorcid 1; Yomna Mohamed1; Hasan Elgarem1; Rasha Eletreby1
1Department of Endemic Medicine and Hepatology, Cairo University, Cairo, Egypt.
2Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt
Abstract
Background: Non-invasive biomarkers have largely replaced liver biopsy in assessment of liver fibrosis in chronic HCV. Autotaxin (ATX) is a novel serum marker that may be related to liver fibrosis. Aim: to clarify the role of ATX as a biomarker for the estimation of hepatic fibrosis and to compare its sensitivity and specificity to the well-known fibrosis-4 score (FIB-4) and the AST-to-Platelet Ratio Index (APRI) before treatment with direct-acting antiviral drugs (DAAs) for chronic HCV as well as six months after the end of treatment. Methods: Plasma samples were obtained from 86 chronic HCV patients with different degrees of liver fibrosis. Routine laboratory, transient elastography (TE) and ultrasonographic assessments were done. Enzyme-linked immunosorbent assay (ELISA) technique was used to detect ATX. Results: ATX, FIB-4, and APRI had AUC of 0.57, 0.95, and 0.92, respectively for the detection of cirrhosis (F4). Baseline ATX was higher in cirrhotic group vs. non-cirrhotic group (250 vs. 210) pg/ml, although the difference was not significant (p= 0.3). Significant improvement of all the laboratory parameters, APRI, FIB-4 and liver stiffness occurred at sustained virological response after 24 weeks (SVR24). Non- significant increase of ATX level was noted six months after the end of treatment. Conclusion: ATX should be considered cautiously as a diagnostic marker for liver fibrosis in patients with chronic HCV.
Keywords
direct-acting antiviral agents; autotaxin; hepatitis C virus; liver fibrosis; value
Statistics
Article View: 480
PDF Download: 171